NCT04244825View on ClinicalTrials.gov

Safety, Pharmacodynamics, and Pharmacokinetics of Orally Administered BLD-2660 in Subjects With IPF

PHASE2WithdrawnINTERVENTIONAL

0

Timeline

Start Date

December 15, 2019

Primary Completion Date

September 14, 2020

Study Completion Date

November 5, 2020

Conditions

Idiopathic Pulmonary Fibrosis

Interventions

DRUG

BLD-2660

BLD-2660 - 150 mg capsules '00' size (PO) BID

DRUG

Control: Placebo

Placebo - 150 mg capsules '00' size (PO) BID

Trial Locations (1)

Unknown

Blade Research Site, London

Sponsors

Lead Sponsor

Blade Therapeutics

All Listed Sponsors

lead

Blade Therapeutics

INDUSTRY

NCT04244825 - Safety, Pharmacodynamics, and Pharmacokinetics of Orally Administered BLD-2660 in Subjects With IPF | Biotech Hunter | Biotech Hunter